MSB trading, page-2427

Agreed. Big Pharma has had every interest in trying to stymie Stem Cell based therapies. But it can't go on for much longer.

In 2017, the United States spent about $3.5 trillion, or 18 percent of GDP, on health expenditures – more than twice the average among developed countries. Of that $3.5 trillion, $1.5 trillion, is directly or indirectly financed by the federal government.

http://www.crfb.org/papers/american-health-care-health-spending-and-federal-budget

"The 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently.

The law builds on FDA's ongoing work to incorporate the perspectives of patients into the development of drugs, biological products, and devices in FDA's decision-making process. Cures enhances our ability to modernize clinical trial designs and clinical outcome assessments, which will speed the development and review of novel medical products, including medical countermeasures.

It also provides new authority to help FDA improve our ability to recruit and retain scientific, technical, and professional experts and it establishes new expedited product development programs, including:

• The Regenerative Medicine Advanced Therapy, or RMAT, that offers a new expedited option for certain eligible biologics products."

https://www.fda.gov/regulatoryinfor...tstothefdcact/21stcenturycuresact/default.htm

And MSB is at the forefront of the Stem Cell revolution. What a time to be alive. What a time to be a shareholder.